Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Huilin wei,

Cepheid, USA

Title: Comparable b2a2/e13a2 and b3a2/e14a2 reporting in Xpert® BCR-ABL ultra when calibrated by WHO IS and by IVT-RNA copy number

Biography

Biography: Huilin wei,

Abstract

Xpert® BCR-ABL Ultra, automated cartridge-based assay for monitoring BCR-ABL transcript levels, is calibrated by WHO IS to standardize the % reporting for both b2a2/e13a2 BCR-ABL (e13a2) and b3a2/e14a2 BCR-ABL (e14a2) relative to control ABL gene in peripheral blood of patients as a standard management of Chronic Myeloid Leukemia (CML). Studies have shown differences in patients carrying e13a2 or e14a2 in molecular response to Tyrosine Kinase Inhibitor (TKI) treatment. Therefore, it is necessary to understand if there is % reporting differences between two transcripts calibrated by WHO IS and explore the calibration method using breakpoint specific RNA input Copy Number (CN) for accurate TKI treatment monitoring.